trending Market Intelligence /marketintelligence/en/news-insights/trending/VDNg_wx-jVJHORYAY7H8lQ2 content esgSubNav
In This List

CTI BioPharma closes preferred stock offering

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


CTI BioPharma closes preferred stock offering

Cell Therapeutics Inc. closed an underwritten public offering of 22,500 series N-3 preferred shares at $2,000 apiece for net proceeds of about $42.8 million.

The company will use the net proceeds to conduct a clinical trial, submit a new marketing authorization application for pacritinib to the European Medicines Agency, conduct additional research for the possible application of pacritinib in indications other than myelofibrosis, complete another clinical trial and for general corporate purposes.

Jefferies LLC acted as the sole book-running manager for the offering, with BTIG LLC as the lead manager.